ADPT — Adaptive Biotechnologies Corporation

Summary of Adaptive Biotechnologies Q4 2025 Earnings Call

1. Key Financial Results and Metrics:

• Q4 2025 Revenue: $71.7 million, a 63% increase year-over-year.
• Full Year 2025 Revenue: $277 million, representing a 55% year-over-year growth.
• Adjusted EBITDA: $4.1 million in Q4, compared to a loss of $16.4 million in Q4 2024; full year adjusted EBITDA was $12.2 million, up from a loss of $80.4 million in 2024.
• Net Loss: $13.6 million for Q4 and $59.5 million for the full year.
• Cash Position: $227 million at year-end, reflecting a 68% reduction in cash burn.

2. Strategic Updates and Business Highlights:

• Minimal Residual Disease (MRD) Business: Revenue grew 46% year-over-year, with clonoSEQ clinical testing revenue increasing 64% for the year.
• Volume Growth: ClonoSEQ tests reached a record 30,038 in Q4, up 43% year-over-year.
• Average Selling Price (ASP): Increased to $1,307 per test, with expectations to reach approximately $1,400 in 2026.
• Integration and Partnerships: Successful integration of clonoSEQ into Flatiron's Onco EMR and two data partnerships with Pfizer for TCR antigen data.
• Immune Medicine Business: Focus on scaling TCR antigen data and monetizing through data licensing, with a disciplined cash burn of around $30 million.

3. Forward Guidance and Outlook:

• 2026 Revenue Guidance for MRD: Expected between $255 million and $265 million, implying 22% growth year-over-year.
• Operating Expenses: Projected to be between $350 million and $360 million, reflecting a 6% increase year-over-year.
• Positive Adjusted EBITDA and Free Cash Flow: Expected by the end of 2026.
• ClonoSEQ Volume Growth: Anticipated to exceed 30% year-over-year, driven by blood-based testing and community penetration.

4. Bad News, Challenges, or Points of Concern:

• Competitive Pressures: Concerns regarding a competitor's flow cytometer product that claims to have comparable sensitivity to clonoSEQ, although Adaptive maintains that their product is significantly more sensitive.
• Execution Risks: Potential risks associated with securing new payer contracts that could impact ASP growth.
• Seasonality and Weather Effects: Q1 is typically lighter due to holidays and weather-related issues, which could affect volume growth.

5. Notable Q&A Insights:

• Volume Trends: Management acknowledged potential seasonality in Q1 and noted that weather-related issues impacted sample arrival but expressed confidence in continued growth.
• Market Penetration: Discussion on strategies to increase penetration in DLBCL, leveraging experiences from multiple myeloma.
• ASP Growth Dynamics: ASP growth is expected to be linear, with a focus on securing favorable contracts with major payers.
• Immune Medicine Strategy: Emphasis on transitioning to a data and informatics business model, with ongoing investments in data generation and partnerships.

Overall, Adaptive Biotechnologies reported strong financial performance in 2025, with significant growth in both revenue and market presence, while also navigating competitive challenges and focusing on strategic partnerships for future growth.